|
Serine/threonine kinases (STKs), especially CHK1 and CHK2 are vital in prostate cancer research, as they maintain genomic integrity and regulate DNA repair. Malfunction of these kinases in advanced prostate cancer increases chromosomal instability and therapeutic resistance, leading to malignant progression of the tumor and reduced therapeutic efficacy. Recent studies show the benefits of targeting these kinases: destabilizing ELK3 to combat chemotherapy resistance, blocking PME-1/PP2Ac interactions to inhibit cancer cell survival, and enhancing existing treatment efficacy through precise kinase inhibition. SignalChem Biotech, now part of Sino Biological, offers high-quality serine/threonine kinase products, including active CHK1 and CHK2 proteins to support biomedical research on targeting kinase-driven mechanisms in cancer.
|
